Compare Five9 Inc (FIVN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Five9 Inc trades at $31.44 (market cap $2.44B), while Regeneron Pharmaceuticals Inc trades at $796.73 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 33.6× Five9 Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Five9 Inc pays none. Which is the better fit depends on your goals.
| FIVN | REGN | |
|---|---|---|
Market Cap | $2.44B | $82.06B |
Sector | Technology | Health |
52-Week High | $34.48 | $812.27 |
52-Week Low | $13.61 | $555.51 |
Enterprise Value | $2.59B | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $34.48, up 1.44% today and near its 52-week high of $34.58. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Revenue growth accelerated to 10% in Q2 2026, driven by AI-powered subscription services, while profitability improved with net income turning positive in 2025 after years of losses.
Outlook remains positive with 61% analyst buy ratings and a consensus price target of $32.67, though current price exceeds this target. Key risks include high valuation multiples (P/E 48), ongoing legal scrutiny regarding fiduciary duties, and competitive pressures in the CX software space. The company's leadership refresh and AI integration provide growth catalysts.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
